A Phase 1, Open-label, Dose Finding Study of CC-93269, a BCMA X CD3 T Cell Engaging Antibody, in Subjects With Relapsed and Refractory Multiple Myeloma.
Phase of Trial: Phase I
Latest Information Update: 06 Nov 2019
Price : $35 *
At a glance
- Drugs CC-93269 (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions; First in man
- Sponsors Celgene Corporation
- 06 Nov 2019 Interim results released at the 61st Annual Meeting and Exposition of the American Society of Hematology
- 22 Jul 2019 Planned number of patients changed from 125 to 120.
- 22 Jul 2019 Status changed from active, no longer recruiting to recruiting.